WallStSmart

Enhabit Inc. (EHAB)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6151% more annual revenue ($66.57B vs $1.06B). MRK leads profitability with a 4.8% profit margin vs -0.3%. EHAB earns a higher WallStSmart Score of 39/100 (F).

EHAB

Hold

39

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EHAB.

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.81

$65.77 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EHAB1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

EHAB4 concerns · Avg: 3.8/10
Revenue GrowthGrowth
1.9%4/10

1.9% revenue growth

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Market CapQuality
$706.91M3/10

Smaller company, higher risk/reward

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : EHAB

The strongest argument for EHAB centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : EHAB

The primary concerns for EHAB are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

EHAB profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

EHAB carries more volatility with a beta of 0.96 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

EHAB scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enhabit Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Enhabit, Inc. provides home health and hospice services in the United States.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?